Allosteric coupling asymmetry mediates paradoxical activation of BRAF by type II inhibitors
eLife · 2024
DOI: 10.7554/elife.95481 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2024. Verfasst von Damien M Rasmussen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of Minnesota, Minneapolis, United States. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Protein Kinase Inhibitors, Protein Multimerization. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NIGMS NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
The type II class of RAF inhibitors currently in clinical trials paradoxically activate BRAF at subsaturating concentrations. Activation is mediated by induction of BRAF dimers, but why activation rather than inhibition occurs remains unclear. Using biophysical methods tracking BRAF dimerization and conformation, we built an allosteric model of inhibitor-induced dimerization that resolves the allosteric contributions of inhibitor binding to the two active sites of the dimer, revealing key differences between type I and type II RAF inhibitors. For type II inhibitors the allosteric coupling between inhibitor binding and BRAF dimerization is distributed asymmetrically across the two dimer binding sites, with binding to the first site dominating the allostery. This asymmetry results in efficient and selective induction of dimers with one inhibited and one catalytically active subunit. Our allosteric models quantitatively account for paradoxical activation data measured for 11 RAF inhibitors. Unlike type II inhibitors, type I inhibitors lack allosteric asymmetry and do not activate BRAF homodimers. Finally, NMR data reveal that BRAF homodimers are dynamically asymmetric with only one of the subunits locked in the active αC-in state. This provides a structural mechanism for how binding of only a single αC-in inhibitor molecule can induce potent BRAF dimerization and activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, University of Minnesota, Minneapolis, United States.
- Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, United States.
- Department of Chemistry, University of Minnesota, Minneapolis, United States.
- Center for Immunology, University of Minnesota, Minneapolis, United States.
- Masonic Cancer Center, University of Minnesota, Minneapolis, United States.
ORCID-Profile: Damien M Rasmussen, David D Thomas, Tanya S Freedman, Nicholas M Levinson
Förderung
- NIAMS NIH HHS
- NIGMS NIH HHS
- NCI NIH HHS
- National Cancer Institute
- National Institute of General Medical Sciences
- American Cancer Society – Kirby Foundation
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Rasmussen, D. M., Semonis, M. M., Greene, J. T., Muretta, J. M., Thompson, A. R., Toledo Ramos, S., Thomas, D. D., Pomerantz, W. C. K., Freedman, T. S., & Levinson, N. M. (2024). Allosteric coupling asymmetry mediates paradoxical activation of BRAF by type II inhibitors. eLife. https://doi.org/10.7554/elife.95481
Vancouver
Rasmussen DM, Semonis MM, Greene JT, Muretta JM, Thompson AR, Toledo Ramos S, et al. Allosteric coupling asymmetry mediates paradoxical activation of BRAF by type II inhibitors. eLife. 2024. doi:10.7554/elife.95481
BibTeX
@article{Rasmussen2024,
author = {Rasmussen, Damien M and Semonis, Manny M and Greene, Joseph T and Muretta, Joseph M and Thompson, Andrew R and Toledo Ramos, Silvia and Thomas, David D and Pomerantz, William C K and Freedman, Tanya S and Levinson, Nicholas M},
title = {Allosteric coupling asymmetry mediates paradoxical activation of BRAF by type II inhibitors},
journal = {eLife},
year = {2024},
doi = {10.7554/elife.95481}
}
EUVIMED